BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7(26): 2648-2663 [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 112] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jiang B, Zhang R, Zhang J, Hou Y, Chen X, Zhou M, Tian X, Hao C, Fan K, Yan X. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy. Theranostics 2019;9:2167-82. [PMID: 31149036 DOI: 10.7150/thno.30867] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
3 Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters 2019;458:123-35. [DOI: 10.1016/j.canlet.2019.05.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
4 Huang T, Xu S, Deo R, Ma A, Li H, Ma K, Gan X. Targeting the Ca2+/Calmodulin-dependent protein kinase II by Tetrandrine in human liver cancer cells. Biochemical and Biophysical Research Communications 2019;508:1227-32. [DOI: 10.1016/j.bbrc.2018.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Li N, Jiang Y, Plantefève R, Michaud F, Nosrati Z, Tremblay C, Saatchi K, Häfeli UO, Kadoury S, Moran G, Joly F, Martel S, Soulez G. Magnetic Resonance Navigation for Targeted Embolization in a Two-Level Bifurcation Phantom. Ann Biomed Eng 2019;47:2402-15. [PMID: 31290038 DOI: 10.1007/s10439-019-02317-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Di Paola M, Quarta A, Conversano F, Sbenaglia EA, Bettini S, Valli L, Gigli G, Casciaro S. Human Hepatocarcinoma Cell Targeting by Glypican-3 Ligand Peptide Functionalized Silica Nanoparticles: Implications for Ultrasound Molecular Imaging. Langmuir 2017;33:4490-9. [DOI: 10.1021/acs.langmuir.7b00327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
7 Guerrini GP, Pinelli D, Marini E, Corno V, Guizzetti M, Zambelli M, Aluffi A, Lincini L, Fagiuoli S, Lucianetti A, Colledan M. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. Prog Transplant 2018;28:63-9. [PMID: 29251164 DOI: 10.1177/1526924817746686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Abdelfattah SN, Haseeb AF, Tawfik MM, Khalil DM, Attia D. Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein. Clin Exp Hepatol 2019;5:140-6. [PMID: 31501790 DOI: 10.5114/ceh.2019.85165] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Lee KF, Chong CCN, Fong AKW, Fung AKY, Lok HT, Cheung YS, Wong J, Lai PBS. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr 2018;7:320-30. [PMID: 30498708 DOI: 10.21037/hbsn.2018.03.17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Hong J, Kim S, Lin PC. Interleukin-33 and ST2 Signaling in Tumor Microenvironment. J Interferon Cytokine Res 2019;39:61-71. [PMID: 30256696 DOI: 10.1089/jir.2018.0044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
12 Wang Y, Sun M, Liu J, Liu Y, Jiang C, Zhu H, Wang W, Wang Y. FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:795-804. [PMID: 31897196 DOI: 10.3892/ol.2019.11183] [Reference Citation Analysis]
13 Huang WT, Chen ZX, He RQ, Wu YZ, Yin SY, Liang XN, Chen G, Yang H, Peng ZG, Yang LH. Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis. Onco Targets Ther 2016;9:5061-71. [PMID: 27574447 DOI: 10.2147/OTT.S111431] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
14 Jeon YJ, Kim S, Kim JH, Youn UJ, Suh SS. The Comprehensive Roles of ATRANORIN, A Secondary Metabolite from the Antarctic Lichen Stereocaulon caespitosum, in HCC Tumorigenesis. Molecules 2019;24:E1414. [PMID: 30974882 DOI: 10.3390/molecules24071414] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
15 Xiao Y, Liu G, Ouyang X, Zai D, Zhou J, Li X, Zhang Q, Zhao J. Loss of ARID1A Promotes Hepatocellular Carcinoma Progression via Up-regulation of MYC Transcription. J Clin Transl Hepatol 2021;9:528-36. [PMID: 34447682 DOI: 10.14218/JCTH.2021.00111] [Reference Citation Analysis]
16 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Yu MM, Feng YH, Zheng L, Zhang J, Luo GH. Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells. World J Gastroenterol 2019; 25(10): 1210-1223 [PMID: 30886504 DOI: 10.3748/wjg.v25.i10.1210] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL Jr. Rahma OE. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother. 2018;67:161-174. [PMID: 29052780 DOI: 10.1007/s00262-017-2082-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
19 Zheng D, Williams C, Vold JA, Nguyen JH, Harnois DM, Bagaria SP, McLaughlin SA, Li Z. Regulation of sex hormone receptors in sexual dimorphism of human cancers. Cancer Lett 2018;438:24-31. [PMID: 30223066 DOI: 10.1016/j.canlet.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Xiao Z, Shen J, Zhang L, Li M, Hu W, Cho C. Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects. Oncol Lett. 2018;15:3395-3402. [PMID: 29467864 DOI: 10.3892/ol.2018.7758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
21 Mahmoud A, Slater K. Hepatocellular Carcinoma Misdiagnosed as a Liver Abscess - A Story of Misdiagnosis and Long-Term Malignant Disease Control. Cureus 2021;13:e12636. [PMID: 33585123 DOI: 10.7759/cureus.12636] [Reference Citation Analysis]
22 Aboelfotoh AO, Foda EM, Elghandour AM, Teama NM, Abouzein RA, Mohamed GA. Talin-1; other than a potential marker for hepatocellular carcinoma diagnosis. Arab J Gastroenterol 2020;21:80-4. [PMID: 32439236 DOI: 10.1016/j.ajg.2020.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Joerger M, Güller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019;10:373-8. [PMID: 31032109 DOI: 10.21037/jgo.2018.11.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
24 Berndt N, Egners A, Mastrobuoni G, Vvedenskaya O, Fragoulis A, Dugourd A, Bulik S, Pietzke M, Bielow C, van Gassel R, Damink SWO, Erdem M, Saez-Rodriguez J, Holzhütter HG, Kempa S, Cramer T. Kinetic modelling of quantitative proteome data predicts metabolic reprogramming of liver cancer. Br J Cancer 2020;122:233-44. [PMID: 31819186 DOI: 10.1038/s41416-019-0659-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
25 Xu D, Sheng JQ, Hu PJ, Huang TS, Lee WC. Predicting hepatocellular carcinoma recurrences: A data-driven multiclass classification method incorporating latent variables. J Biomed Inform 2019;96:103237. [PMID: 31238108 DOI: 10.1016/j.jbi.2019.103237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
27 Yu Z, Li Y, Han T, Liu Z. Demethylation of the HACE1 gene promoter inhibits the proliferation of human liver cancer cells. Oncol Lett 2019;17:4361-8. [PMID: 30988809 DOI: 10.3892/ol.2019.10139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 2017;8:46691-703. [PMID: 28493839 DOI: 10.18632/oncotarget.17358] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 15.5] [Reference Citation Analysis]
29 Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J, Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10:501-510. [PMID: 26856326 DOI: 10.1007/s12072-015-9700-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
30 Liu L, Wang H, Liu Q, Duan M, Dong X, Zhu D, Zhu Y, Leng X. Biodistribution of TAT-LHRH conjugated chitosan/DNA nanoparticles in the mice bearing hepatoma xenografts: Biodistribution of TAT-LHRH Conjugated Chitosan/DNA Nanoparticles. J Biomed Mater Res 2016;104:2394-400. [DOI: 10.1002/jbm.a.35775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
31 Dewdney B, Roberts A, Qiao L, George J, Hebbard L. A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. Biomolecules 2020;10:E496. [PMID: 32218179 DOI: 10.3390/biom10040496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Gerum S, Heinz C, Belka C, Walter F, Paprottka PM, De Toni EN, Roeder F. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting. Strahlenther Onkol 2020;196:334-48. [DOI: 10.1007/s00066-019-01540-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
34 Weiskirchen R. Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:183-7. [PMID: 27115013 DOI: 10.3978/j.issn.2304-3881.2016.02.04] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
35 Opo FADM, Rahman MM, Ahammad F, Ahmed I, Bhuiyan MA, Asiri AM. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci Rep 2021;11:4049. [PMID: 33603068 DOI: 10.1038/s41598-021-83626-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
36 Vohra I, Attar B, Katiyar V, Palacios P, Randhawa T, Baig MA, Flores E, Wang Y, Mutneja H, Sharma S, Lingamneni P, Farooq MZ, Bhaskaran N, Gandhi S, Vettiankal G, Demetria M. Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma. J Gastrointest Cancer 2021;52:201-6. [PMID: 32128703 DOI: 10.1007/s12029-020-00373-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Di Leo L, Vegliante R, Ciccarone F, Salvatori I, Scimeca M, Bonanno E, Sagnotta A, Grazi GL, Aquilano K, Ciriolo MR. Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53. Oncogene 2019;38:1860-75. [PMID: 30367149 DOI: 10.1038/s41388-018-0545-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
38 Wang ZD, Qu FY, Chen YY, Ran ZS, Liu HY, Zhang HD. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ Sci B 2017;18:27-36. [PMID: 28070994 DOI: 10.1631/jzus.B1600205] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
39 Gerum S, Heinz C, Belka C, Walter F, Paprottka P, De Toni EN, Roeder F. Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease. Radiat Oncol. 2018;13:100. [PMID: 29843752 DOI: 10.1186/s13014-018-1048-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
40 Amicone L, Marchetti A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:24. [PMID: 29971255 DOI: 10.21037/tgh.2018.04.05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
41 Kosmidis C, Varsamis N, Anthimidis G, Baka S, Valoukas D, Koletsa T, Zarampouka K, Koimtzis G, Georgakoudi E, Zarogoulidis P, Efthymiadis C. Primary hepatocellular carcinoma in a patient with history of treated breast cancer: a case report with challenging diagnosis and treatment. Int J Gen Med 2018;11:399-403. [PMID: 30349348 DOI: 10.2147/IJGM.S176052] [Reference Citation Analysis]
42 Ding H, Ye ZH, Wen DY, Huang XL, Zeng CM, Mo J, Jiang YQ, Li JJ, Cai XY, Yang H, Chen G. Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance. Mol Med Rep 2017;16:5393-405. [PMID: 28849100 DOI: 10.3892/mmr.2017.7275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
43 Tsai PH, Wang ML, Chang JH, Yarmishyn AA, Nhi Nguyen PN, Chen W, Chien Y, Huo TI, Mou CY, Chiou SH. Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. ACS Appl Mater Interfaces 2019;11:19808-18. [PMID: 31066542 DOI: 10.1021/acsami.9b04474] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
44 Pinal-García DF, Nuño-Guzmán CM, Gómez-Abarca A, Corona JL, Espejo I. Spontaneous Rupture of Hepatocellular Carcinoma in a Young Patient with Fatal Outcome. Case Rep Gastroenterol 2018;12:19-26. [PMID: 29515341 DOI: 10.1159/000486193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Bo C, Li N, Li X, Liang X, An Y. Long noncoding RNA uc.338 promotes cell proliferation through association with BMI1 in hepatocellular carcinoma. Human Cell 2016;29:141-7. [DOI: 10.1007/s13577-016-0140-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
46 Juarez-Flores A, José MV. Multivariate Entropy Characterizes the Gene Expression and Protein-Protein Networks in Four Types of Cancer. Entropy (Basel) 2018;20:E154. [PMID: 33265245 DOI: 10.3390/e20030154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Matsushita J, Suzuki T, Okamura K, Ichihara G, Nohara K. Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes. Environ Health Prev Med 2020;25:31. [PMID: 32703154 DOI: 10.1186/s12199-020-00871-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 R D, P R. An Optimized HCC Recurrence Prediction Using APO Algorithm Multiple Time Series Clinical Liver Cancer Dataset. J Med Syst. 2019;43:193. [PMID: 31115780 DOI: 10.1007/s10916-019-1265-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
49 Dong W, Dai ZH, Liu FC, Guo XG, Ge CM, Ding J, Liu H, Yang F. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. EBioMedicine 2019;45:155-67. [PMID: 31235426 DOI: 10.1016/j.ebiom.2019.06.030] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 19.3] [Reference Citation Analysis]
50 Wang Q, Zhang X, Liao H, Sun Y, Ding L, Teng Y, Zhu W, Zhang Z, Duan Y. Multifunctional Shell-Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma. Adv Funct Mater 2018;28:1706124. [DOI: 10.1002/adfm.201706124] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
51 Li W, Xiao X, Li X, Xu Y, Ma L, Guo L, Yan C, Wu Y. Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments. Contrast Media Mol Imaging 2018;2018:9169072. [PMID: 30275801 DOI: 10.1155/2018/9169072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
52 Chen HA, Li CC, Lin YJ, Wang TF, Chen MC, Su YH, Yeh YL, Padma VV, Liao PH, Huang CY. Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells. Aging (Albany NY) 2021;13:12046-57. [PMID: 33901009 DOI: 10.18632/aging.202908] [Reference Citation Analysis]
53 Krause GC, Lima KG, Levorse V, Haute GV, Gassen RB, Garcia MC, Pedrazza L, Donadio MVF, Luft C, de Oliveira JR. Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells. EXCLI J 2019;18:540-8. [PMID: 31611738 DOI: 10.17179/excli2019-1415] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
54 Hemmingsson J, Högberg J, Mölne J, Svensson J, Gjertsson P, Rizell M, Henrikson O, Bernhardt P. Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities. Adv Radiat Oncol 2018;3:439-46. [PMID: 30202811 DOI: 10.1016/j.adro.2018.04.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Yue D, Sun X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death Dis 2018;9:935. [PMID: 30224718 DOI: 10.1038/s41419-018-0960-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
56 Jeng KS, Jeng CJ, Jeng WJ, Chang CF, Sheen IS. Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma. Oncol Lett 2017;14:1905-10. [PMID: 28789425 DOI: 10.3892/ol.2017.6396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
57 Ha E, Kim F, Blanchard J, Juon HS. Prevalence of Chronic Hepatitis B and C Infection in Mongolian Immigrants in the Washington, District of Columbia, Metropolitan Area, 2016-2017. Prev Chronic Dis 2019;16:E08. [PMID: 30676936 DOI: 10.5888/pcd16.180104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Apidechkul T. Seroprevalence and factors associated with hepatitis B virus infection among the hill tribe youths, northern Thailand. BMC Infect Dis 2019;19:125. [PMID: 30727952 DOI: 10.1186/s12879-019-3747-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Tang W, Zhao Z, Wang C, Ye T, Yang B. Molecular design and optimization of hepatic cancer SLP76-derived PLCγ1 SH3-binding peptide with the systematic N-substitution of peptide PXXP motif. J Mol Recognit 2019;32:e2806. [PMID: 31397025 DOI: 10.1002/jmr.2806] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Tak H, Kang H, Ji E, Hong Y, Kim W, Lee EK. Potential use of TIA-1, MFF, microRNA-200a-3p, and microRNA-27 as a novel marker for hepatocellular carcinoma. Biochem Biophys Res Commun 2018;497:1117-22. [PMID: 29496454 DOI: 10.1016/j.bbrc.2018.02.189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
61 Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget 2017;8:10510-22. [PMID: 28060737 DOI: 10.18632/oncotarget.14446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
62 Chen CT, Lee HL, Chiou HL, Chou CH, Wang PH, Yang SF, Chou YE. Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development. PLoS One 2018;13:e0198967. [PMID: 29889892 DOI: 10.1371/journal.pone.0198967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Omar HA, Zaher DM, Srinivasulu V, Hersi F, Tarazi H, Al-Tel TH. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma. Eur J Med Chem 2017;139:804-14. [PMID: 28865276 DOI: 10.1016/j.ejmech.2017.08.054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget 2017;8:77734-51. [PMID: 29100421 DOI: 10.18632/oncotarget.20774] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
65 Sun T, Han J, Liu S, Wang X, Wang ZY, Xie Z. Tailor-Made Semiconducting Polymers for Second Near-Infrared Photothermal Therapy of Orthotopic Liver Cancer. ACS Nano 2019;13:7345-54. [PMID: 31188558 DOI: 10.1021/acsnano.9b03910] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 26.7] [Reference Citation Analysis]
66 Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV. A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol. 2016;89:263-272. [PMID: 26668215 DOI: 10.1124/mol.115.101360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
67 Siniprasad P, Nair B, Balasubramaniam V, Sadanandan P, Namboori PK, Nath LR. Evaluation of Kaempferol as AKT Dependent mTOR Regulator via Targeting FKBP-12 in Hepatocellular Carcinoma: An In silico Approach. LDDD 2020;17:1401-8. [DOI: 10.2174/1570180817999200623115703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Jain R, Frederick JP, Huang EY, Burke KE, Mauger DM, Andrianova EA, Farlow SJ, Siddiqui S, Pimentel J, Cheung-Ong K, McKinney KM, Köhrer C, Moore MJ, Chakraborty T. MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct. Nucleic Acid Ther 2018;28:285-96. [PMID: 30088967 DOI: 10.1089/nat.2018.0734] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
69 Bonferoni MC, Gavini E, Rassu G, Maestri M, Giunchedi P. Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials (Basel) 2020;10:E870. [PMID: 32365938 DOI: 10.3390/nano10050870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
70 Song D, Xu B, Shi D, Li S, Cai Y. S100A6 promotes proliferation and migration of HepG2 cells via increased ubiquitin-dependent degradation of p53. Open Med (Wars) 2020;15:317-26. [PMID: 33335992 DOI: 10.1515/med-2020-0101] [Reference Citation Analysis]
71 Ling N, Zhou X, Ji Y, Li W, Ji C, Qi Z. Immuno-modulatory and cellular antioxidant activities of κ-selenocarrageenan in combination with Epirubicin in H22 hepatoma-bearing mice. Biomed Pharmacother 2017;91:132-7. [PMID: 28448867 DOI: 10.1016/j.biopha.2017.04.064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
72 Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
73 Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med 2018;60:185-91. [PMID: 29856183 DOI: 10.23736/S0031-0808.18.03472-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
74 Sun JY, Zhang XY, Cao YZ, Zhou X, Gu J, Mu XX. Diagnostic and prognostic value of circular RNAs in hepatocellular carcinoma. J Cell Mol Med 2020;24:5438-45. [PMID: 32281724 DOI: 10.1111/jcmm.15258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
75 Böttger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev 2020;154-155:79-101. [PMID: 32574575 DOI: 10.1016/j.addr.2020.06.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
76 Fei X, Zhang P, Pan Y, Liu Y. MicroRNA-98-5p Inhibits Tumorigenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma by Targeting NF-κB-Inducing Kinase. Yonsei Med J 2020;61:460-70. [PMID: 32469170 DOI: 10.3349/ymj.2020.61.6.460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Sourbier C. Plasma HSP90α and liver cancer: a potential biomarker? EBioMedicine 2017;25:7-8. [PMID: 29037606 DOI: 10.1016/j.ebiom.2017.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
78 Christian-Miller N, Frenette C. Hepatocellular cancer pain: impact and management challenges. J Hepatocell Carcinoma 2018;5:75-80. [PMID: 30050880 DOI: 10.2147/JHC.S145450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen Jr MS. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World J Gastroenterol 2016; 22(38): 8584-8595 [PMID: 27784971 DOI: 10.3748/wjg.v22.i38.8584] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
80 Lin H, Yang B, Teng M. T-cell immunoglobulin mucin-3 as a potential inducer of the epithelial-mesenchymal transition in hepatocellular carcinoma. Oncol Lett 2017;14:5899-905. [PMID: 29113224 DOI: 10.3892/ol.2017.6961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
81 Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol 2017; 9(36): 1305-1314 [PMID: 29359013 DOI: 10.4254/wjh.v9.i36.1305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
82 Naeli P, Pourhanifeh MH, Karimzadeh MR, Shabaninejad Z, Movahedpour A, Tarrahimofrad H, Mirzaei HR, Bafrani HH, Savardashtaki A, Mirzaei H, Hamblin MR. Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role. Crit Rev Oncol Hematol 2020;145:102854. [PMID: 31877535 DOI: 10.1016/j.critrevonc.2019.102854] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 27.7] [Reference Citation Analysis]
83 Hang X, Wu Z, Chu K, Yu G, Peng H, Xin H, Miao X, Wang J, Xu W. Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients. Tumor Biol 2016;37:15079-85. [DOI: 10.1007/s13277-016-5302-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
84 Hu P, Cheng D, Huang T, Banizs AB, Xiao J, Liu G, Chen Q, Wang Y, He J, Shi H. Evaluation of Novel 64Cu-Labeled Theranostic Gadolinium-Based Nanoprobes in HepG2 Tumor-Bearing Nude Mice. Nanoscale Res Lett 2017;12:523. [PMID: 28875472 DOI: 10.1186/s11671-017-2292-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
85 Zhou Y, Shi WY, He W, Yan ZW, Liu MH, Chen J, Yang YS, Wang YQ, Chen GQ, Huang Y. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Exp Cell Res 2020;387:111714. [PMID: 31711919 DOI: 10.1016/j.yexcr.2019.111714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
86 Sherif ZA, Nouraie SM, Lee E, Aduli F, Brim H, Ashktorab H. Trends in the Incidence of Hepatocellular Carcinoma in Washington DC: A Single Institutional Cohort Study (1959-2013). J Natl Med Assoc 2021;113:396-404. [PMID: 33648723 DOI: 10.1016/j.jnma.2021.02.001] [Reference Citation Analysis]
87 Quencer KB, Friedman T, Sheth R, Oklu R. Tumor thrombus: incidence, imaging, prognosis and treatment. Cardiovasc Diagn Ther 2017;7:S165-77. [PMID: 29399520 DOI: 10.21037/cdt.2017.09.16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
88 Wang H, Mejia MC, Gonzalez SJ, Zoorob RJ, Chai W, Du XL. Cancer incidence and survival trends among infants in the United States from 1975 to 2014. Pediatr Blood Cancer 2021;68:e28917. [PMID: 33470510 DOI: 10.1002/pbc.28917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Cui H, Dai G, Guan J. Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World. Onco Targets Ther 2020;13:143-9. [PMID: 32021262 DOI: 10.2147/OTT.S234868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 de Oliveira da Silva B, Alberici LC, Ramos LF, Silva CM, da Silveira MB, Dechant CRP, Friedman SL, Sakane KK, Gonçalves LR, Moraes KCM. Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. Int J Biochem Cell Biol 2018;98:137-55. [PMID: 29524604 DOI: 10.1016/j.biocel.2018.02.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
91 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Sempokuya T, Patel KP, Azawi M, Ma J, Wong LL. Increased morbidity and mortality of hepatocellular carcinoma patients in lower cost of living areas. World J Clin Cases 2021; 9(23): 6734-6746 [PMID: 34447820 DOI: 10.12998/wjcc.v9.i23.6734] [Reference Citation Analysis]
93 Shah SS, Wu TT, Torbenson MS, Chandan VS. Aberrant CDX2 expression in hepatocellular carcinomas: An important diagnostic pitfall. Hum Pathol. 2017;64:13-18. [PMID: 28089540 DOI: 10.1016/j.humpath.2016.12.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
94 Arora SP, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol 2020;11:557-65. [PMID: 31704038 DOI: 10.1016/j.jgo.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Wasmer MH, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol 2016;7:682. [PMID: 28119694 DOI: 10.3389/fimmu.2016.00682] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
96 Nevzorova YA, Grossmann J, Trautwein C. Anti-tumorigenic and anti-angiogenic effects of natural conifer Abies sibirica terpenoids in vivo and in vitro. Biomedicine & Pharmacotherapy 2017;89:386-95. [DOI: 10.1016/j.biopha.2017.02.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
97 Cha DI, Jang KM, Kim SH, Kang TW, Song KD. Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Eur Radiol 2017;27:4394-405. [DOI: 10.1007/s00330-017-4804-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
98 Hu P, Fu Z, Liu G, Tan H, Xiao J, Shi H, Cheng D. Gadolinium-Based Nanoparticles for Theranostic MRI-Guided Radiosensitization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2019;7:368. [PMID: 31828068 DOI: 10.3389/fbioe.2019.00368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
99 Jin X, Cai L, Wang C, Deng X, Yi S, Lei Z, Xiao Q, Xu H, Luo H, Sun J. CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3. Cell Death Dis 2018;9:318. [PMID: 29476051 DOI: 10.1038/s41419-018-0350-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
100 Scollon S, Anglin AK, Thomas M, Turner JT, Wolfe Schneider K. A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes. J Genet Couns 2017;26:387-434. [PMID: 28357779 DOI: 10.1007/s10897-017-0077-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
101 Koirala N, Das D, Fayazzadeh E, Sen S, McClain A, Puskas JE, Drazba JA, McLennan G. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A 2019;107:2522-35. [PMID: 31334591 DOI: 10.1002/jbm.a.36758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
102 Gowthami J, Gururaj N, Mahalakshmi V, Sathya R, Sabarinath TR, Doss DM. Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review. J Oral Maxillofac Pathol 2020;24:293-307. [PMID: 33456239 DOI: 10.4103/jomfp.JOMFP_348_19] [Reference Citation Analysis]
103 Nabi AA, Atta SA, El-Ahwany E, Elzayat E, Saleh H. Taurine Upregulates miRNA-122-5p Expression and Suppresses the Metabolizing Enzymes of Glycolytic Pathway in Hepatocellular Carcinoma. Mol Biol Rep 2021;48:5549-59. [PMID: 34313924 DOI: 10.1007/s11033-021-06571-y] [Reference Citation Analysis]
104 García-Vilas JA, Medina MÁ. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol 2018; 24(33): 3695-3708 [PMID: 30197476 DOI: 10.3748/wjg.v24.i33.3695] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
105 Bevilacqua V, Brunetti A, Trotta GF, Carnimeo L, Marino F, Alberotanza V, Scardapane A. A Deep Learning Approach for Hepatocellular Carcinoma Grading: . International Journal of Computer Vision and Image Processing 2017;7:1-18. [DOI: 10.4018/ijcvip.2017040101] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Mansour GH, El-Magd MA, Mahfouz DH, Abdelhamid IA, Mohamed MF, Ibrahim NS, Hady A Abdel Wahab A, Elzayat EM. Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells. Bioorg Chem 2021;116:105329. [PMID: 34544028 DOI: 10.1016/j.bioorg.2021.105329] [Reference Citation Analysis]
107 Maioli M, Basoli V, Carta P, Fabbri D, Dettori MA, Cruciani S, Serra PA, Delogu G. Synthesis of magnolol and honokiol derivatives and their effect against hepatocarcinoma cells. PLoS One. 2018;13:e0192178. [PMID: 29415009 DOI: 10.1371/journal.pone.0192178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
108 Yan H, Jung KH, Kim J, Rumman M, Oh MS, Hong S. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway. Biomedicine & Pharmacotherapy 2018;98:134-41. [DOI: 10.1016/j.biopha.2017.12.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
109 Van Haele M, Roskams T. Hepatic Progenitor Cells: An Update. Gastroenterol Clin North Am. 2017;46:409-420. [PMID: 28506372 DOI: 10.1016/j.gtc.2017.01.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
110 Lee HY, Chen CK, Ho CM, Lee SS, Chang CY, Chen KJ, Jou YS. EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma. Oncotarget 2018;9:13193-205. [PMID: 29568350 DOI: 10.18632/oncotarget.24149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
111 Kruit H, Joseph Francis K, Rascevska E, Manohar S. Annular Fiber Probe for Interstitial Illumination in Photoacoustic Guidance of Radiofrequency Ablation. Sensors (Basel) 2021;21:4458. [PMID: 34209996 DOI: 10.3390/s21134458] [Reference Citation Analysis]
112 Qiu L, Tang Q, Li G, Chen K. Long non-coding RNAs as biomarkers and therapeutic targets: Recent insights into hepatocellular carcinoma. Life Sci 2017;191:273-82. [PMID: 28987633 DOI: 10.1016/j.lfs.2017.10.007] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
113 Valanejad L, Timchenko N. Akt-FoxO1 axis controls liver regeneration. Hepatology 2016;63:1424-6. [PMID: 27100144 DOI: 10.1002/hep.28440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
114 Amiri A, Hastert FD, Dietz C. Carcinomas with Occult Metastasis Potential: Diagnosis/Prognosis Accuracy Improvement by Means of Force Spectroscopy. Adv Biosyst 2020;4:e2000042. [PMID: 32558372 DOI: 10.1002/adbi.202000042] [Reference Citation Analysis]